Printer Friendly

CrystalGenomics secures USD2.6m in strategic equity investment from KSLSF.

M2 PHARMA-January 17, 2012-CrystalGenomics secures USD2.6m in strategic equity investment from KSLSF(C)2012 M2 COMMUNICATIONS

17 January 2012 - South Korean biopharmaceutical company CrystalGenomics Inc said on Friday it had secured KRW3bn (USD2.6m/EUR2.1m) in a private placement to the Korea Seoul Life Science Fund (KSLSF).

This is the third time within the past month that the company has secured capital following a KRW10bn bond issuance to KDB Capital and another KRW10bn in bonds issued to Tube Investment.

The company said it will use proceeds to support its R&D including three clinical stage therapeutic programmes.

(KRW1000 = USD0.873/EUR0.685)

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 17, 2012
Words:115
Previous Article:PuraMed BioScience names Sue Baacke CFO.
Next Article:Scil Proteins in supply agreement with Actavis over Reteplease.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters